{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:46:40Z","timestamp":1790063200899,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The most severe complication associated with giant coronary aneurysm in children with Kawasaki disease is ischemic cardiomyopathy (ICM) caused by thrombosis. Addition of tissue plasminogen activator, Alteplase, in the treatment regimen can be an efficient thrombolytic therapy, and therefore can have a significantly positive impact on patients\u2019 quality of life in long term.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Total four male KD patients with central thromboses in coronary aneurysm were treated in Pediatric Cardiology Department of Shengjing Hospital, China Medical University, from January 2020 to August 2021. These patients received thrombolytic treatments including Alteplase once +\u2009Heparin for 1 week followed by continuous oral Warfarin\u2009+\u2009Aspirin\u2009+\u2009Clopidogrel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>4 young male KD patients had coronary aneurysm (CAA) complicated with total 7 occurrences of central thrombosis. These patients were given alteplase and heparin\/oral Warfarin\u2009+\u2009Aspirin\u2009+\u2009Clopidogrel treatment. 9 days to 2 months later, thromboses were significantly dissolved. The treatment successfully diminished the thrombosis complication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>1. Pediatric KD patients complicated with coronary aneurysm thrombosis are prone to recurrence of thrombosis. 2.\u00a0 In KD patients complicated with coronary aneurysm thrombosis, treatments described in Method can be used for treating either small thromboses formed less than 1 month with strong echo and convex lumen or large thromboses with mixed strong and weak echo. With these treatments, coronary artery blood flow can be improved or completely recovered. 3. Clinical experiences at our center in treating these KD patients suggest that Alteplase can be considered in thrombolytic treatment beyond the limitation of less than 12\u00a0h of thrombosis occurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-022-00767-7","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T07:03:04Z","timestamp":1670223784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of thrombosis in KD Patients using tissue plasminogen activator: a single center study"],"prefix":"10.1186","volume":"20","author":[{"given":"Yanqiu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanmei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-2899","authenticated-orcid":false,"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"767_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/INF.0000000000000914","volume":"35","author":"JJ Chen","year":"2016","unstructured":"Chen JJ, Ma XJ, Liu F, Yan WL, Huang MR, Huang M. et al. Epidemiologic features of Kawasaki disease in Shanghai from 2008 through 2012. Pediatr Infect DisJ.(2016), 35:7\u201312. doi:https:\/\/doi.org\/10.1097\/INF.0000000000000914.","journal-title":"Pediatr Infect DisJ"},{"key":"767_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-030-19055-2_4","volume-title":"Periodic and Non-Periodic Fevers. Rare Disease soft he Immune System","author":"RK Pilania","year":"2020","unstructured":"Pilania RK, Singh S. Kawasaki Disease. In: Cimaz R, editors. Periodic and Non-Periodic Fevers. Rare Disease soft he Immune System. Cham: Springer (; 2020. pp.\u00a045\u201363. doi:https:\/\/doi.org\/10.1007\/978-3-030-19055-2_4. In. : )."},{"key":"767_CR3","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"13","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;13:e927-99. https:\/\/doi.org\/10.1161\/CIR.0000000000000484.","journal-title":"Circulation."},{"key":"767_CR4","doi-asserted-by":"publisher","unstructured":"Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association Pediatrics. 2004;114(6):1708\u201333. https:\/\/doi.org\/10.1542\/peds.2004-2182 Erratum in: Pediatrics. (2005),115(4):1118.","DOI":"10.1542\/peds.2004-2182"},{"key":"767_CR5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.amjcard.2016.08.039","volume":"118","author":"JY Lo","year":"2016","unstructured":"Lo JY, Minich LL, Tani LY, Wilkes J, Ding Q, Menon SC. Factors Associated With Resource Utilization and Coronary Artery Dilation in Refractory Kawasaki Disease (from the Pediatric Health Information System Database). Am J Cardiol. (2016),118:1636\u201340. DOI: 10.1016\/ j.amjcard.2016.08.039.","journal-title":"Am J Cardiol"},{"key":"767_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1089253215573328","volume":"19","author":"PN Jone","year":"2015","unstructured":"Jone PN, Tapia D, Davidson J, Fagan TE, Browne L, Ing RJ, Kay J. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease. Semin Cardiothorac Vasc Anesth. 2015;19:255\u20139. doi:https:\/\/doi.org\/10.1177\/1089253215573328.","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"767_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00246-010-9781-y","volume":"31","author":"R Vijay","year":"2010","unstructured":"Vijay R, Karia GC, Hescock A, Gedalia, et al. Successful emergent coronary thrombolysis in a neonate with Kawasaki\u2019s disease. Pediatr Cardiol. 2010;31:1239\u201342. doi:https:\/\/doi.org\/10.1007\/s00246-010-9781-y.","journal-title":"Pediatr Cardiol"},{"key":"767_CR8","first-page":"651","volume":"13","author":"RH Chandwaney","year":"2001","unstructured":"Chandwaney RH, Stathopoulos T, Sunew J, et al. Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki\u2019s disease. J Invesive cardil. 2001;13:651\u20133 PMID: 11533505.","journal-title":"J Invesive cardil"},{"issue":"2","key":"767_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1442-200x.2005.02033.x","volume":"47","author":"M Ayusawa","year":"2005","unstructured":"Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N,et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int (. 2005;47(2):232\u20134. doi:https:\/\/doi.org\/10.1111\/j.1442-200x.2005.02033.x.","journal-title":"Pediatr Int ("},{"key":"767_CR10","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1161\/01.cir.98.25.2805","volume":"98","author":"CP Cannon","year":"1998","unstructured":"Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK- tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial.\u00a0Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98:2805\u201314. https:\/\/doi.org\/10.1161\/01.cir.98.25.2805.","journal-title":"Circulation"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1345\/aph.1D565","volume":"38","author":"RC Gosselin","year":"2004","unstructured":"Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004;38:1383\u20138. doi:https:\/\/doi.org\/10.1345\/aph.1D565.","journal-title":"Ann Pharmacother"},{"key":"767_CR12","doi-asserted-by":"publisher","first-page":"e4589","DOI":"10.7759\/cureus.4589","volume":"11","author":"M Fayyaz","year":"2019","unstructured":"Fayyaz M, Abbas F, Kashif T. The Role of\u2002Warfarin\u2002and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis. Cureus. 2019;11:e4589. doi:https:\/\/doi.org\/10.7759\/cureus.4589.","journal-title":"Cureus"},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.thromres.2007.10.018","volume":"122","author":"B Shenkman","year":"2008","unstructured":"Shenkman B, Matetzky S, Fefer P, Hod H, Einav Y, Lubetsky A, et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res (2008), 122:336\u201345. doi: https:\/\/doi.org\/10.1016\/j.thromres.2007.10.018.","journal-title":"Thromb Res"},{"key":"767_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ehjcvp\/pvz059","volume":"6","author":"Z Ying-Ying","year":"2020","unstructured":"Ying-Ying Z, Ting-Ting W, Yi Y, Xian-Geng H, Ying G, You C, et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Eur Heart J Cardiovasc Pharmacother. (2020), 6:211\u201321. doi: https:\/\/doi.org\/10.1093\/ehjcvp\/pvz059.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"767_CR15","doi-asserted-by":"publisher","unstructured":"Park JH, Choi HJ. Clinical implications of\u2002thrombocytosis\u2002in acute phase Kawasaki disease.Eur J Pediatr. (2021), Feb 1. doi: https:\/\/doi.org\/10.1007\/s00431-021-03966-8. Online ahead of print.","DOI":"10.1007\/s00431-021-03966-8"},{"key":"767_CR16","doi-asserted-by":"publisher","unstructured":"Nishino S, Kodaka T, Sawada Y, Goka T, Gotoh Y, Tsunemine H, et al. Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. J Clin Exp Hematop. (2018), 58:166\u201370. doi: https:\/\/doi.org\/10.3960\/jslrt.18016.","DOI":"10.3960\/jslrt.18016"},{"key":"767_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-0038-1_12","volume-title":"Paediatric Kawasaki Disease","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang Y, Hou Y, Yu X. Misdiagnosed KD. In: Wang H, editor. Paediatric Kawasaki Disease. Singapore: Springer; 2021. https:\/\/doi.org\/10.1007\/978-981-15-0038-1_12."},{"key":"767_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fped","author":"ChuY-q XuY-m","year":"2021","unstructured":"XuY-m ChuY-q, Wang LiX-m, MaQ-m C, Yu X-n, Yu X-y, Chen R, Xing Y-l, Yu X-x, Sun L, Cui X-z, Wang H. The Complementary Relationship Between Echocardiography and Multi-Slice Spiral CT Coronary Angiography in the Diagnosis of Coronary Artery Thrombosis in Children With Kawasaki Disease. Front Pediatr 9:670887. 2021. doi:https:\/\/doi.org\/10.3389\/fped. 2021.670887.","journal-title":"Front Pediatr 9:670887"},{"issue":"11","key":"767_CR19","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.13813","volume":"15","author":"A Greinacher","year":"2017","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017 Nov;15(11):2099\u2013114. doi:10.1111\/ jth.13813. Epub 2017 Sep 28.","journal-title":"J Thromb Haemost"},{"key":"767_CR20","doi-asserted-by":"publisher","unstructured":"Arora K, Guleria S, Jindal AK, Rawat A, Singh S. Platelets in Kawasaki disease: Is this only a numbers game or something beyond? Genes Dis. (2019). PMID:32181276. https:\/\/doi.org\/10.1016\/j.gendis.2019.09.003.","DOI":"10.1016\/j.gendis.2019.09.003"},{"key":"767_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1253\/circj.cj-12-1037","volume":"78","author":"T Yahata","year":"2014","unstructured":"Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J. 2014;78:188\u201393. https:\/\/doi.org\/10.1253\/circj.cj-12-1037 Epub 2013 Oct 22.","journal-title":"Circ J."},{"key":"767_CR22","doi-asserted-by":"publisher","unstructured":"Berthelot JM, Drouet L, Liot\u00e9 F. Kawasaki-like diseases and thrombotic coagulopathy in COVID- 19: delayed over-activation of the STING pathway? Emerg Microbes Infect. 2020;9(1):1514\u201322. https:\/\/doi.org\/10.1080\/22221751.2020.1785336.","DOI":"10.1080\/22221751.2020.1785336"},{"key":"767_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000007046","volume":"94","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Watanabe N, Okuno M, Okamoto N, Fujino H. Effects of intracoronary tissue-type plasminogen activator treatment in Kawasaki disease and acute myocardial infarction. Cardiology. 2000;94:52\u20137. https:\/\/doi.org\/10.1159\/000007046.","journal-title":"Cardiology"},{"key":"767_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/hrt.78.5.517","volume":"78","author":"H Horigome","year":"1997","unstructured":"Horigome H, Sekijima T, Miyamoto T. Successful thrombolysis with intracoronary adminis- tration of tissue plasminogen activator in an infant with Kawasaki disease. Heart. 1997;78:517\u20138. doi:https:\/\/doi.org\/10.1136\/hrt.78.5.517.","journal-title":"Heart"},{"key":"767_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00794192","volume":"16","author":"S Tsubata","year":"1995","unstructured":"Tsubata S, Ichida F, Hamamichi Y, Miyazaki A, Hashimoto I, Okada T. Successful throm- bolytic therapy using tissue type plasminogen activator in Kawasaki disease. Pediatr Cardiol. 1995;16:186\u20139. https:\/\/doi.org\/10.1007\/BF00794192.","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"767_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/hrt.78.6.621","volume":"78","author":"F Katayama","year":"1997","unstructured":"Katayama F, Hiraishi S, Takeda N, Misawa H. Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction. Heart. 1997;78(6):621\u20132. https:\/\/doi.org\/10.1136\/hrt.78.6.621.","journal-title":"Heart."},{"key":"767_CR27","doi-asserted-by":"publisher","first-page":"CD004437","DOI":"10.1002\/14651858.CD004437.pub5","volume":"12","author":"H Qiukui","year":"2018","unstructured":"Qiukui H, Bi Rong D, Jirong Y, Taixiang W, Guan JL. Thrombolytic therapy\u2002for pulmonary embolism. Cochrane Database Syst Rev. 2018;12:CD004437. https:\/\/doi.org\/10.1002\/14651858.CD004437.pub5 Published online (2018) Dec 18.","journal-title":"Cochrane Database Syst Rev"},{"key":"767_CR28","doi-asserted-by":"publisher","first-page":"e110444","DOI":"10.1371\/journal","volume":"9","author":"R Matsuo","year":"2014","unstructured":"Matsuo R, Kamouchi M, Fukuda H, Hata J, Wakisaka Y, Kuroda J, et al. Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry. PLoS One. 2014;9:e110444. https:\/\/doi.org\/10.1371\/journal Published online 2014 Oct 16.","journal-title":"PLoS One"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00767-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T07:08:38Z","timestamp":1670224118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00767-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00767-7","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was discussed by the Ethics Committee of Shengjing Hospital affiliated to China Medical University and Consent to participate the study (supplementary figure).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent has been given by the patients and parents, via the written informed co","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}